Rocket Pharmaceuticals Inc. (9IP1)

Overview

Rocket Pharmaceuticals, Inc. operates as a pioneering entity in the biotechnology sector, with its efforts primarily directed towards the development of gene therapies aimed at addressing rare and severe diseases. This late-stage biotech company, founded in 1999 and based in Cranbury, New Jersey, leverages cutting-edge technology and scientific research to create transformative treatments for patients living with genetic disorders that currently have limited or no therapeutic options. By focusing on the power of gene therapy, Rocket Pharmaceuticals aims to chart a new course in medicine, particularly in the realm of rare diseases, showcasing a strong commitment to improving patient outcomes through innovation and research.

Products and Services

• Fanconi Anemia Therapy:

  A clinical-stage program utilizing ex vivo lentiviral vectors to treat Fanconi anemia, a genetic condition that impairs bone marrow, thus reducing blood cell production or generating defective blood cells. This therapy aims to correct the genetic defect and restore normal bone marrow function, offering hope to patients with this rare condition.

• Leukocyte Adhesion Deficiency-I Therapy:

  This program focuses on treating leukocyte adhesion deficiency-I, a genetic disorder that disrupts immune system functionality due to the body’s inability to produce a sufficient number of certain types of white blood cells. Through gene therapy, Rocket Pharmaceuticals seeks to correct the underlying genetic cause, potentially providing a significant improvement in immune system function.

• Pyruvate Kinase Deficiency Therapy:

  Targeting pyruvate kinase deficiency, this clinical-stage program uses ex vivo lentiviral vectors to address a rare autosomal recessive disorder that leads to chronic non-spherocytic hemolytic anemia. By fixing the genetic malfunction, the therapy could normalize red blood cell metabolism and prevent anemia, thereby improving quality of life for affected individuals.

• Danon Disease Program:

  In the realm of in vivo gene therapy, Rocket Pharmaceuticals conducts a clinical stage program for Danon disease, a lysosomal-associated disorder that significantly affects heart function and can lead to early mortality. The therapy aims to correct the genetic aberrations causing the disease, with the goal of treating or significantly delaying the progression of heart failure.

• Plakophilin-2 Arrhythmogenic Cardiomyopathy Therapy:

  This program aims to treat Plakophilin-2 Arrhythmogenic Cardiomyopathy, a genetic cardiac disorder that can lead to heart disease. By targeting the genetic root of the disorder, Rocket Pharmaceuticals’ gene therapy could potentially offer a groundbreaking treatment to manage or cure this inheritable cardiac condition.

• BAG3 Dilated Cardiomyopathy Program:

  Focusing on BAG3 Dilated Cardiomyopathy, this clinical stage program seeks to offer a gene therapy solution for another genetic cardiac disorder known to cause heart failure. The therapy is designed to correct the genetic mutations responsible for the disease, potentially offering patients an opportunity for a healthier and extended life.